<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_glioma" title="Promising Prognosis Marker Candidates on the Status of Epithelial – Mesenchymal Transition and Glioma Stem Cells in Glioblastoma" shortTitle="glioma" author="Yasuo Takashima, Atsushi Kawaguchi, Ryuya Yamanaka" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2073-4409/8/11/1312/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
1.	LS	1.
Introduction	NN	introduction
</s>
</head>
<p>
<s type="decl">
The	DT	the
World	NNP	World
Health	NNP	Health
Organization	NNP	Organization
(	-LRB-	(
WHO	NNP	WHO
)	-RRB-	)
classifies	VBZ	classify
gliomas	NNS	glioma
into	IN	into
four	CD	4
categories	NNS	category
based	VBN	base
on	IN	on
malignancy	NN	malignancy
and	CC	and
overall	JJ	overall
survival	NN	survival
(	-LRB-	(
OS	NNP	OS
)	-RRB-	)
.	.	.
</s>
<s type="decl">
Glioblastoma	NNP	Glioblastoma
is	VBZ	be
the	DT	the
most	RBS	most
malignant	JJ	malignant
form	NN	form
of	IN	of
astrocytoma	NN	astrocytoma
that	WDT	that
is	VBZ	be
fast-growing	VBG	fast-grow
(	-LRB-	(
grade	NN	grade
4	CD	4
glioma	NN	glioma
)	-RRB-	)
.	.	.
</s>
<s type="decl">
The	DT	the
median	JJ	median
OS	NN	OS
of	IN	of
glioblastoma	NN	glioblastoma
is	VBZ	be
9	CD	9
–	SYM	-
15	CD	15
months	NNS	month
and	CC	and
the	DT	the
five-year	JJ	five-year
survival	NN	survival
rate	NN	rate
remains	VBZ	remain
less	JJR	less
than	IN	than
5	CD	5
%	NN	%
.	.	.
</s>
<s type="decl">
Radiotherapy	NN	radiotherapy
with	IN	with
six	CD	6
cycles	NNS	cycle
of	IN	of
concomitant	JJ	concomitant
temozolomide	NN	temozolomide
,	,	,
an	DT	a
oral	JJ	oral
alkylating	JJ	alkylating
agent	NN	agent
with	IN	with
minimal	JJ	minimal
additional	JJ	additional
toxicity	NN	toxicity
,	,	,
is	VBZ	be
the	DT	the
standard	JJ	standard
treatment	NN	treatment
after	IN	after
surgery	NN	surgery
in	IN	in
glioblastoma	NN	glioblastoma
patients	NNS	patient
.	.	.
</s>
<s type="decl">
Thus	RB	thus
,	,	,
there	EX	there
is	VBZ	be
an	DT	a
immediate	JJ	immediate
requirement	NN	requirement
for	IN	for
the	DT	the
early	JJ	early
diagnosis	NN	diagnosis
and	CC	and
precise	JJ	precise
prediction	NN	prediction
of	IN	of
the	DT	the
prognosis	NN	prognosis
for	IN	for
treatments	NNS	treatment
of	IN	of
glioblastoma	NN	glioblastoma
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
invasiveness	NN	invasiveness
of	IN	of
glioblastoma	NN	glioblastoma
depends	VBZ	depend
on	IN	on
its	PRP$	its
high	JJ	high
infiltration	NN	infiltration
potential	NN	potential
to	TO	to
invade	VB	invade
the	DT	the
basement	NN	basement
membranes	NNS	membrane
of	IN	of
surrounding	VBG	surround
tissues	NNS	tissue
.	.	.
</s>
<s type="decl">
Glioma	NN	glioma
cells	NNS	cell
are	VBP	be
reprogrammed	VBN	reprogramm
to	TO	to
have	VB	have
increased	VBN	increase
motility	NN	motility
via	IN	via
weakened	VBN	weaken
cell	NN	cell
adhesions	NNS	adhesion
and	CC	and
a	DT	a
dysregulated	VBN	dysregulate
cytoskeleton	NN	cytoskeleton
;	:	;
this	DT	this
is	VBZ	be
known	VBN	know
as	IN	as
epithelial	JJ	epithelial
–	SYM	-
mesenchymal	NN	mesenchymal
transition	NN	transition
(	-LRB-	(
EMT	NNP	EMT
)	-RRB-	)
.	.	.
</s>
<s type="decl">
EMT	NNP	EMT
is	VBZ	be
a	DT	a
biological	JJ	biological
process	NN	process
that	WDT	that
polarized	VBD	polarize
epithelial	JJ	epithelial
cell	NN	cell
sheets	NNS	sheet
undergo	VBP	undergo
,	,	,
wherein	VBP	wherein
multiple	JJ	multiple
biochemical	JJ	biochemical
changes	NNS	change
culminate	VBP	culminate
in	IN	in
mesenchymal	JJ	mesenchymal
phenotypes	NNS	phenotype
.	.	.
</s>
<s type="decl">
Cells	NNS	cell
display	VBP	display
altered	VBN	alter
morphology	NN	morphology
,	,	,
resistance	NN	resistance
to	IN	to
chemotherapy	NN	chemotherapy
,	,	,
and	CC	and
<hi rend="italic">
anoikis	NN	anoikis
</hi>
(	-LRB-	(
a	DT	a
form	NN	form
of	IN	of
programmed	VBN	programme
cell	NN	cell
death	NN	death
of	IN	of
cells	NNS	cell
detached	VBN	detach
from	IN	from
the	DT	the
basement	NN	basement
membranes	NNS	membrane
)	-RRB-	)
.	.	.
</s>
<s type="decl">
EMT	NNP	EMT
is	VBZ	be
also	RB	also
involved	VBN	involve
in	IN	in
other	JJ	other
biological	JJ	biological
processes	NNS	process
,	,	,
including	VBG	include
implantation	NN	implantation
and	CC	and
embryo	NN	embryo
development	NN	development
,	,	,
wound	NN	wind
healing	NN	healing
,	,	,
tissue	NN	tissue
regeneration	NN	regeneration
,	,	,
and	CC	and
neoplasia	NN	neoplasia
associated	VBN	associate
with	IN	with
cancer	NN	cancer
progression	NN	progression
.	.	.
</s>
<s type="decl">
During	IN	during
invasion	NN	invasion
in	IN	in
cancer	NN	cancer
,	,	,
phenotypes	NNS	phenotype
also	RB	also
change	VBP	change
as	IN	as
EMT	NNP	EMT
is	VBZ	be
mainly	RB	mainly
induced	VBN	induce
by	IN	by
hypoxia	NN	hypoxia
and	CC	and
the	DT	the
transforming	VBG	transform
growth	NN	growth
factor	NN	factor
(	-LRB-	(
TGF)-β	NN	TGF)-β
released	VBN	release
from	IN	from
glioma	NN	glioma
stem	NN	stem
cells	NNS	cell
(	-LRB-	(
GSCs	NNS	GSC
)	-RRB-	)
,	,	,
mesenchymal	NN	mesenchymal
stem	NN	stem
cells	NNS	cell
(	-LRB-	(
MSCs	NNS	MSC
)	-RRB-	)
,	,	,
and	CC	and
myeloid	NN	myeloid
cells	NNS	cell
recruited	VBN	recruit
by	IN	by
hypoxia	NN	hypoxia
.	.	.
</s>
<s type="decl">
The	DT	the
reverse	NN	reverse
is	VBZ	be
also	RB	also
essential	JJ	essential
for	IN	for
the	DT	the
formation	NN	formation
of	IN	of
distant	JJ	distant
or	CC	or
disseminated	VBN	disseminate
tumor	NN	tumor
nodules	NNS	nodule
.	.	.
</s>
</p>
<p>
<s type="decl">
Stem	NN	stem
cells	NNS	cell
,	,	,
including	VBG	include
cancer	NN	cancer
stem	NN	stem
cells	NNS	cell
(	-LRB-	(
CSCs	NNS	CSC
)	-RRB-	)
,	,	,
are	VBP	be
pluripotent	JJ	pluripotent
and	CC	and
capable	JJ	capable
of	IN	of
self-renewal	NN	self-renewal
,	,	,
like	IN	like
induced	VBN	induce
pluripotent	NN	pluripotent
stem	NN	stem
(	-LRB-	(
iPS	NNP	iPS
)	-RRB-	)
cells	NNS	cell
induced	VBN	induce
by	IN	by
the	DT	the
transcription	NN	transcription
factors	NNS	factor
Oct3/4	NNP	Oct3/4
,	,	,
Sox2	NNP	Sox2
,	,	,
c-Myc	NNP	c-Myc
,	,	,
and	CC	and
Klf4	NNP	Klf4
or	CC	or
OCT4	NNP	OCT4
,	,	,
SOX2	NNP	SOX2
,	,	,
NANOG	NNP	NANOG
,	,	,
and	CC	and
LIN28	NNP	LIN28
.	.	.
</s>
<s type="decl">
The	DT	the
expression	NN	expression
of	IN	of
OCT4	NNP	OCT4
,	,	,
MYC	NNP	MYC
,	,	,
and	CC	and
KLF4	NNP	KLF4
increases	VBZ	increase
with	IN	with
increasing	VBG	increase
malignancy	NN	malignancy
in	IN	in
astrocytomas	NNS	astrocytoma
,	,	,
whereas	IN	whereas
MYC	NNP	MYC
expression	NN	expression
slightly	RB	slightly
decreases	VBZ	decrease
in	IN	in
recurrent	JJ	recurrent
glioblastomas	NNS	glioblastoma
.	.	.
</s>
<s type="decl">
Exposure	NN	exposure
to	IN	to
temozolomide	NN	temozolomide
(	-LRB-	(
TMZ	NNP	TMZ
)	-RRB-	)
increases	VBZ	increase
the	DT	the
expression	NN	expression
of	IN	of
KLF4	NNP	KLF4
and	CC	and
reduces	VBZ	reduce
the	DT	the
expression	NN	expression
of	IN	of
Nanog	NNP	Nanog
and	CC	and
OCT4	NNP	OCT4
in	IN	in
glioma	NN	glioma
cells	NNS	cell
,	,	,
indicating	VBG	indicate
that	IN	that
stem	NN	stem
cell	NN	cell
factors	NNS	factor
,	,	,
especially	RB	especially
KLF4	NNP	KLF4
,	,	,
play	VBP	play
pivotal	JJ	pivotal
roles	NNS	role
in	IN	in
GSCs	NNPS	GSC
.	.	.
</s>
<s type="decl">
The	DT	the
most	RBS	most
common	JJ	common
GSC	NNP	GSC
marker	NN	marker
CD133	NNP	CD133
,	,	,
also	RB	also
known	VBN	know
as	IN	as
prominin-1	NN	prominin-1
(	-LRB-	(
<hi rend="italic">
PROM1	NNP	PROM1
</hi>
)	-RRB-	)
,	,	,
is	VBZ	be
used	VBN	use
to	TO	to
isolate	VB	isolate
GSCs	NNPS	GSC
by	IN	by
fluorescence-activated	JJ	fluorescence-activated
cell	NN	cell
sorting	NN	sorting
(	-LRB-	(
FACS	NNP	FACS
)	-RRB-	)
in	IN	in
primary	JJ	primary
glioma	NN	glioma
tissues	NNS	tissue
and	CC	and
the	DT	the
cell	NN	cell
lines	NNS	line
U87	NNP	U87
and	CC	and
T98G	NNP	T98G
.	.	.
</s>
<s type="decl">
There	EX	there
are	VBP	be
changes	NNS	change
in	IN	in
metabolism	NN	metabolism
in	IN	in
glioma	NN	glioma
and	CC	and
oxidative	JJ	oxidative
phosphorylation	NN	phosphorylation
,	,	,
glycolysis	NN	glycolysis
,	,	,
and	CC	and
glutaminolysis	NN	glutaminolysis
replace	VBP	replace
redox	NN	redox
balance	NN	balance
,	,	,
bioenergetics	NN	bioenergetics
,	,	,
and	CC	and
biosynthesis	NN	biosynthesis
,	,	,
respectively	RB	respectively
.	.	.
</s>
<s type="decl">
Tumor	NN	tumor
progression	NN	progression
is	VBZ	be
enhanced	VBN	enhance
by	IN	by
inflammation	NN	inflammation
,	,	,
which	WDT	which
is	VBZ	be
an	DT	a
emerging	VBG	emerge
hallmark	NN	hallmark
of	IN	of
cancers	NNS	cancer
that	WDT	that
depends	VBZ	depend
on	IN	on
the	DT	the
balance	NN	balance
of	IN	of
glioma	NN	glioma
cell	NN	cell
proliferation	NN	proliferation
,	,	,
migration	NN	migration
,	,	,
and	CC	and
escape	NN	escape
from	IN	from
the	DT	the
immune	JJ	immune
system	NN	system
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
the	DT	the
correlation	NN	correlation
between	IN	between
EMT	NNP	EMT
and	CC	and
GSCs	NNS	GSC
in	IN	in
glioblastoma	NN	glioblastoma
has	VBZ	have
not	RB	not
been	VBN	be
reported	VBN	report
to	IN	to
date	NN	date
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
this	DT	this
study	NN	study
,	,	,
we	PRP	we
focused	VBD	focus
on	IN	on
EMT	NNP	EMT
and	CC	and
GSCs	NN	GSC
and	CC	and
performed	VBD	perform
multivariable	JJ	multivariable
analyses	NNS	analysis
using	VBG	use
the	DT	the
expression	NN	expression
data	NNS	datum
and	CC	and
OS	NN	OS
in	IN	in
patients	NNS	patient
with	IN	with
glioblastoma	NN	glioblastoma
.	.	.
</s>
<s type="decl">
To	TO	to
determine	VB	determine
the	DT	the
distribution	NN	distribution
of	IN	of
survival	NN	survival
of	IN	of
glioblastoma	NN	glioblastoma
patients	NNS	patient
,	,	,
we	PRP	we
composed	VBD	compose
prognosis	NN	prognosis
prediction	NN	prediction
formulae	NN	formulae
for	IN	for
the	DT	the
following	VBG	follow
components	NNS	component
:	:	:
</s>
<s type="frag">
epithelium	NN	epithelium
(	-LRB-	(
EPI	NNP	EPI
)	-RRB-	)
,	,	,
mesenchyme	NN	mesenchyme
(	-LRB-	(
MES	NNP	MES
)	-RRB-	)
,	,	,
glioma	NN	glioma
(	-LRB-	(
GLI	NNP	GLI
)	-RRB-	)
,	,	,
GSC	NNP	GSC
,	,	,
molecular	JJ	molecular
target	NN	target
therapy	NN	therapy
(	-LRB-	(
MTT	NNP	MTT
)	-RRB-	)
genes	NNS	gene
,	,	,
and	CC	and
potential	JJ	potential
glioma	NN	glioma
biomarkers	NNS	biomarker
(	-LRB-	(
PGBs	NNS	PGB
)	-RRB-	)
.	.	.
</s>
<s type="decl">
Consequently	RB	consequently
,	,	,
several	JJ	several
candidate	NN	candidate
genes	NNS	gene
were	VBD	be
identified	VBN	identify
as	IN	as
promising	JJ	promising
glioblastoma	NN	glioblastoma
predictors	NNS	predictor
.	.	.
</s>
</p>
</text>